BofA cuts target for Vertex Pharma stock from USD 672 to USD 667

Published on 10/16/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BofA kept Buy while cutting its target to USD 667 from USD 672 on October 12, 2026. Vertex Pharma stock trades at EUR 453.55 on October 16, 2026.

Target revision and clinical data

BofA Securities cut its Vertex target from USD 672 to USD 667 on October 12, 2026.
Second-quarter 2026 revenue reached USD 3.33 billion, up 12.00 percent year over year.
Vertex Pharma stock trades at EUR 453.55 at 9:19 a.m. CEST at Lang & Schwarz on October 16, 2026.

Bauhaus-Poster mit geometrischen Formen, Molekülsymbol und großem Schriftzug PHARMA — Vertex Pharma US92532F1003 zeigt ein geometrisches Bauhaus-Poster mit Sektor-Text PHARMA und stilisierter Molekülgrafik, Illustration mit AI erstellt.

Vertex Pharma (ISIN US92532F1003) saw BofA Securities cut its price target from USD 672 to USD 667 while maintaining a Buy rating on October 12, 2026, according to Investing.com. The revision puts near-term attention on cystic fibrosis product sales before the next results release.

What does the target cut change?

BofA projected third-quarter Trikafta revenue of USD 2.42 billion, below its cited consensus of USD 2.54 billion, while forecasting ALYFTREK revenue of USD 688.00 million. The same note projected USD 83.00 million from Casgevy and USD 68.00 million from Journavx, according to Investing.com. The figures show why the established CF franchise remains central to the analyst view.

Three milestones shape the story

Vertex reported second-quarter 2026 revenue of USD 3.33 billion, up 12.00 percent from the prior-year quarter, with GAAP net income of USD 1.10 billion, according to TickerScout. The company had reported first-quarter 2026 revenue of USD 2.99 billion on May 4, 2026, after full-year 2025 revenue of USD 12.00 billion was reported on February 12, 2026. On October 9, 2026, Vertex presented interim ALYFTREK data from 48 children aged 2 to 5; 18 children, or 37.50 percent, discontinued pancreatic enzyme replacement therapy, as reported by FinanzNachrichten.

When is the next reporting date?

Vertex is scheduled to report third-quarter 2026 results on November 2, 2026, according to Investing.com. That report will test the product assumptions behind BofA's revised target.

Vertex stock trades in morning action

Vertex Pharma was trading at EUR 453.55 at Lang & Schwarz on October 16, 2026 at 9:19 a.m. CEST. The primary listing is Nasdaq in USD, where the company was last reported at USD 508.75 on October 15, 2026.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.